ERCC1 and gastric cancer: The results of a study among Iranian patients with colorectal and gastric cancers showed no significant association between genetic variations in the ERCC1 rs11615 SNP and response to oxaliplatin-based chemotherapy.30 Consistent with these findings, no significant effect of ERCC1 polymorphisms on treatment response was observed in NSCLC patients receiving cisplatin-based chemotherapy.